Boston eyes drug-eluting stent opportunity in diabetics
This article was originally published in Clinica
Executive Summary
Boston Scientific is eyeing diabetics with coronary artery disease as a promising market for its paclitaxel-eluting stent, based on the results of the product's pivotal clinical trial released last week. But company officials warn that additional clinical data will be needed to support that view.